First Biosimilar to Pegfilgrastim Approved by FDA


The FDA has approved pegfilgrastim-jmdb (Fulphila, Mylan GmbH) as the first biosimilar to pegfilgrastim (Neulasta) to help reduce the chance of fever-causing infection for a population of patients with cancer.

The FDA has approved pegfilgrastim-jmdb (Fulphila, Mylan GmbH) as the first biosimilar to pegfilgrastim (Neulasta). The drug is used to decrease the chance of infection, with fever, associated with an abnormally low number of infection-fighting white blood cells in patients with nonbone marrow cancer who are receiving myelosuppressive chemotherapy that has a clinically significant incidence of febrile neutropenia.

“Bringing new biosimilars to patients is a top priority for the FDA, and a key part of our efforts to help promote competition that can reduce drug costs and promote access,” said FDA Commissioner Scott Gottlieb, MD, in a press release. “We’ll continue to prioritize reviews of these products to help ensure that biosimilar medications are brought to the market efficiently, and through a process that makes certain that these new medicines meet the FDA’s rigorous standard for approval."

The FDA’s approval of pegfilgrastim-jmdb is based on review of evidence that included extensive structural and functional characterization, animal study data, human pharmacokinetic and pharmacodynamic data, clinical immunogenicity data, and other clinical safety and effectiveness data that demonstrates that pegfilgrastim-jmdb is biosimilar to pegfilgrastim. Pegfilgrastim-jmdb has been approved as a biosimilar, not as an interchangeable product.

The most common adverse effects of pegfilgrastim-jmdb are bone pain, and pain in extremities. Patients with a history of serious allergic reactions to human granulocyte colony-stimulating factors, such as pegfilgrastim or filgrastim products, are advised not to take pegfilgrastim-jmdb. Serious adverse effects from treatment with pegfilgrastim-jmdb include rupture of the spleen, acute respiratory distress syndrome, serious allergic reactions (including anaphylaxis), acute inflammation of the kidney, an abnormally high level of white blood cells, capillary leak syndrome, and the potential for tumor growth. Fatal sickle cell crises also have occurred.

According to Gottlieb, the FDA is planning to release a comprehensive new plan this summer to advance new policy efforts that promote biosimilar product development. "Biologics represent some of the most clinically important, but also costliest products that patients use to promote their health. We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from competition to existing biologics once lawful intellectual property has lapsed on these products,” said Gottlieb, in a statement.


FDA approves first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment [news release]. Silver Spring, MD: June 4, 2018; FDA website. Accessed June 4, 2018.

Related Videos
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U -
Image credit: Andrea Izzotti
Inflation Reduction Act is shown using the text and the US flag - Image credit: Andrii |
Pharmacy Interior | Image Credit: Tyler Olson -
Male pharmacist selling medications at drugstore to a senior woman customer | Image Credit: Zamrznuti tonovi -
Pharmacist assists senior woman in buying medicine in pharmacy - Image credit: Drazen |
Pharmacy, medicine and senior woman consulting pharmacist on prescription. Healthcare, shopping and elderly female in consultation with medical worker for medication box, pills or product in store - Image credit: C Daniels/ |
Image credit: fidaolga -
Pharmacists checking inventory at hospital pharmacy- Image credit: Jacob Lund |
Young male pharmacist giving prescription medications to senior female customer in a pharmacy | Image Credit: Zamrznuti tonovi -
© 2023 MJH Life Sciences

All rights reserved.